HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: NASDAQ.COM
- Clinical Trial Success: HUTCHMED's Fanregratinib achieved a 42.5% objective response rate in the pivotal Phase 2 registrational study for intrahepatic cholangiocarcinoma, successfully meeting its primary endpoint and demonstrating potential in treating advanced patients.
- Drug Application Progress: The New Drug Application for Fanregratinib has been accepted for priority review by the Chinese National Medical Products Administration in December 2025, based on Phase 2 trial data, accelerating its path to commercialization.
- Safety Assessment: Among treated patients, 48.3% reported drug-related adverse events of Grade 3 or higher, primarily elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome, indicating a safety profile consistent with known FGFR inhibitor mechanisms.
- Future Presentation Plans: The trial results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 4, 2024, in Munich, Germany, which is expected to further enhance Fanregratinib's market visibility and clinical recognition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCM
Wall Street analysts forecast HCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.160
Low
22.00
Averages
22.00
High
22.00
Current: 10.160
Low
22.00
Averages
22.00
High
22.00
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fanregratinib Shows Promising Results in ICC Treatment
- Clinical Trial Results: Fanregratinib achieved an objective response rate of 42.5% in a pivotal Phase II registration study for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusions/rearrangements, highlighting its potential as a new treatment option, particularly for those previously treated with chemotherapy.
- Survival Data: The study reported a median overall survival of 16.6 months with no treatment-related deaths, indicating significant clinical value in improving patient survival rates and the potential to reshape treatment paradigms in this challenging patient population.
- Safety Profile: While 48.3% of patients experienced drug-related adverse events of Grade 3 or higher, the treatment discontinuation rate was only 2.2%, demonstrating a favorable safety profile for Fanregratinib, making it suitable for broader clinical application.
- Regulatory Progress: The New Drug Application (NDA) for Fanregratinib has been accepted for priority review by the China National Medical Products Administration, marking a significant step towards its potential market launch in China and enhancing HUTCHMED's competitive position in the global biopharmaceutical landscape.
See More
HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
- Clinical Trial Success: HUTCHMED's Fanregratinib achieved a 42.5% objective response rate in the pivotal Phase 2 registrational study for intrahepatic cholangiocarcinoma, successfully meeting its primary endpoint and demonstrating potential in treating advanced patients.
- Drug Application Progress: The New Drug Application for Fanregratinib has been accepted for priority review by the Chinese National Medical Products Administration in December 2025, based on Phase 2 trial data, accelerating its path to commercialization.
- Safety Assessment: Among treated patients, 48.3% reported drug-related adverse events of Grade 3 or higher, primarily elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome, indicating a safety profile consistent with known FGFR inhibitor mechanisms.
- Future Presentation Plans: The trial results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 4, 2024, in Munich, Germany, which is expected to further enhance Fanregratinib's market visibility and clinical recognition.
See More
HUTCHMED Reports Phase III Results for Sovleplenib in wAIHA
- Clinical Trial Success: HUTCHMED's Sovleplenib demonstrated a durable response rate of 66% in the Phase III ESLIM-02 study, significantly higher than the 15% in the placebo group, indicating strong efficacy in treating wAIHA and potentially enhancing market acceptance.
- Significant Market Potential: The market for wAIHA is projected to grow from $0.6 billion in 2025 to $0.93 billion by 2030, with a CAGR of 9.2%, providing a robust commercial foundation for Sovleplenib's market entry.
- Favorable Safety Profile: Sovleplenib exhibited a favorable safety profile, with 43% of patients experiencing grade 3 or higher treatment-emergent adverse events compared to 59% in the placebo group, indicating a competitive edge in safety.
- Rapid Response Time: The median time to response for Sovleplenib was 3.1 weeks, significantly shorter than the 6.3 weeks for placebo, with longer response duration, highlighting its potential advantages in clinical application and attracting investor interest.
See More
Sovleplenib Shows Promising Results in wAIHA Treatment
- Clinical Trial Results: The ESLIM-02 study demonstrated that sovleplenib achieved a durable response rate of 66% in 90 treated patients, significantly surpassing the 15% in the placebo group (p<0.0001), indicating its substantial potential in treating wAIHA.
- Safety Profile: Sovleplenib exhibited a favorable safety profile with grade ≥3 adverse events occurring in 43% of patients, lower than the 59% in the placebo group, and no treatment-related deaths or discontinuations reported, highlighting its viability for clinical use.
- Significant Treatment Effects: During the 24-week double-blind treatment period, sovleplenib significantly reduced the proportion of patients requiring rescue therapy (16% vs 54%, p=0.0001), with 50% of patients able to taper or discontinue glucocorticoids, thereby enhancing patient quality of life.
- Regulatory Progress: Sovleplenib has received priority review from the China National Medical Products Administration and accepted a New Drug Application in April 2026, marking significant regulatory advancements in the treatment landscape for wAIHA and indicating potential market opportunities ahead.
See More
HUTCHMED to Present New Data at ASCO Meeting
- Key Study Results: HUTCHMED will present pivotal Phase II study results of savolitinib at the 2026 ASCO Annual Meeting, demonstrating a 32.3% objective response rate in MET-amplified gastric cancer patients in China, exceeding the pre-specified efficacy threshold and highlighting the drug's potential in treatment.
- Clinical Data Support: As of the October 8, 2025 data cut-off, savolitinib showed a disease control rate of 63.1%, a median time to response of 1.4 months, and a median duration of response of 9.7 months, providing strong support for the New Drug Application submission to the China National Medical Products Administration.
- Diverse Study Presentations: HUTCHMED will also showcase results from various studies of fruquintinib across multiple tumor indications, including the FRESCO and FRUSICA series, further validating its efficacy and safety in different cancer types.
- Strategic Implications: This data presentation not only enhances HUTCHMED's influence in the global oncology treatment landscape but may also accelerate market access for its products, strengthening the company's position in the competitive biopharmaceutical market.
See More
HUTCHMED and Innovent's Drug Combination Approved in China
- Drug Combination Approved: The combination of ELUNATE and TYVYT developed by HUTCHMED and Innovent has received approval from the China National Medical Products Administration for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR-TKI therapy, marking a significant advancement in RCC treatment in China.
- Clinical Trial Data Support: The Phase 3 FRUSICA-2 trial demonstrated a 63% reduction in the risk of disease progression or death with the combination therapy compared to monotherapy, with a median progression-free survival of 22.2 months versus 6.9 months for the control group, indicating strong clinical applicability.
- Significant Efficacy: The combination achieved an objective response rate of 60.5%, significantly higher than the control group's 24.3%, with a median duration of response of 23.7 months, showcasing consistent efficacy across various IMDC prognostic risk groups and reinforcing its therapeutic position.
- Market Impact: This approval marks the tenth indication for TYVYT in China, highlighting its role as a widely used PD-1 inhibitor in the oncology landscape and providing new treatment options for patients, addressing the urgent need for second-line therapies.
See More
Fanregratinib Shows Promising Results in ICC Treatment
- Clinical Trial Results: Fanregratinib achieved an objective response rate of 42.5% in a pivotal Phase II registration study for advanced intrahepatic cholangiocarcinoma (ICC) patients with FGFR2 fusions/rearrangements, highlighting its potential as a new treatment option, particularly for those previously treated with chemotherapy.
- Survival Data: The study reported a median overall survival of 16.6 months with no treatment-related deaths, indicating significant clinical value in improving patient survival rates and the potential to reshape treatment paradigms in this challenging patient population.
- Safety Profile: While 48.3% of patients experienced drug-related adverse events of Grade 3 or higher, the treatment discontinuation rate was only 2.2%, demonstrating a favorable safety profile for Fanregratinib, making it suitable for broader clinical application.
- Regulatory Progress: The New Drug Application (NDA) for Fanregratinib has been accepted for priority review by the China National Medical Products Administration, marking a significant step towards its potential market launch in China and enhancing HUTCHMED's competitive position in the global biopharmaceutical landscape.
See More
HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
- Clinical Trial Success: HUTCHMED's Fanregratinib achieved a 42.5% objective response rate in the pivotal Phase 2 registrational study for intrahepatic cholangiocarcinoma, successfully meeting its primary endpoint and demonstrating potential in treating advanced patients.
- Drug Application Progress: The New Drug Application for Fanregratinib has been accepted for priority review by the Chinese National Medical Products Administration in December 2025, based on Phase 2 trial data, accelerating its path to commercialization.
- Safety Assessment: Among treated patients, 48.3% reported drug-related adverse events of Grade 3 or higher, primarily elevated liver enzymes and palmar-plantar erythrodysesthesia syndrome, indicating a safety profile consistent with known FGFR inhibitor mechanisms.
- Future Presentation Plans: The trial results will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 4, 2024, in Munich, Germany, which is expected to further enhance Fanregratinib's market visibility and clinical recognition.
See More
HUTCHMED Reports Phase III Results for Sovleplenib in wAIHA
- Clinical Trial Success: HUTCHMED's Sovleplenib demonstrated a durable response rate of 66% in the Phase III ESLIM-02 study, significantly higher than the 15% in the placebo group, indicating strong efficacy in treating wAIHA and potentially enhancing market acceptance.
- Significant Market Potential: The market for wAIHA is projected to grow from $0.6 billion in 2025 to $0.93 billion by 2030, with a CAGR of 9.2%, providing a robust commercial foundation for Sovleplenib's market entry.
- Favorable Safety Profile: Sovleplenib exhibited a favorable safety profile, with 43% of patients experiencing grade 3 or higher treatment-emergent adverse events compared to 59% in the placebo group, indicating a competitive edge in safety.
- Rapid Response Time: The median time to response for Sovleplenib was 3.1 weeks, significantly shorter than the 6.3 weeks for placebo, with longer response duration, highlighting its potential advantages in clinical application and attracting investor interest.
See More
Sovleplenib Shows Promising Results in wAIHA Treatment
- Clinical Trial Results: The ESLIM-02 study demonstrated that sovleplenib achieved a durable response rate of 66% in 90 treated patients, significantly surpassing the 15% in the placebo group (p<0.0001), indicating its substantial potential in treating wAIHA.
- Safety Profile: Sovleplenib exhibited a favorable safety profile with grade ≥3 adverse events occurring in 43% of patients, lower than the 59% in the placebo group, and no treatment-related deaths or discontinuations reported, highlighting its viability for clinical use.
- Significant Treatment Effects: During the 24-week double-blind treatment period, sovleplenib significantly reduced the proportion of patients requiring rescue therapy (16% vs 54%, p=0.0001), with 50% of patients able to taper or discontinue glucocorticoids, thereby enhancing patient quality of life.
- Regulatory Progress: Sovleplenib has received priority review from the China National Medical Products Administration and accepted a New Drug Application in April 2026, marking significant regulatory advancements in the treatment landscape for wAIHA and indicating potential market opportunities ahead.
See More
HUTCHMED to Present New Data at ASCO Meeting
- Key Study Results: HUTCHMED will present pivotal Phase II study results of savolitinib at the 2026 ASCO Annual Meeting, demonstrating a 32.3% objective response rate in MET-amplified gastric cancer patients in China, exceeding the pre-specified efficacy threshold and highlighting the drug's potential in treatment.
- Clinical Data Support: As of the October 8, 2025 data cut-off, savolitinib showed a disease control rate of 63.1%, a median time to response of 1.4 months, and a median duration of response of 9.7 months, providing strong support for the New Drug Application submission to the China National Medical Products Administration.
- Diverse Study Presentations: HUTCHMED will also showcase results from various studies of fruquintinib across multiple tumor indications, including the FRESCO and FRUSICA series, further validating its efficacy and safety in different cancer types.
- Strategic Implications: This data presentation not only enhances HUTCHMED's influence in the global oncology treatment landscape but may also accelerate market access for its products, strengthening the company's position in the competitive biopharmaceutical market.
See More
HUTCHMED and Innovent's Drug Combination Approved in China
- Drug Combination Approved: The combination of ELUNATE and TYVYT developed by HUTCHMED and Innovent has received approval from the China National Medical Products Administration for patients with locally advanced or metastatic renal cell carcinoma who have failed prior VEGFR-TKI therapy, marking a significant advancement in RCC treatment in China.
- Clinical Trial Data Support: The Phase 3 FRUSICA-2 trial demonstrated a 63% reduction in the risk of disease progression or death with the combination therapy compared to monotherapy, with a median progression-free survival of 22.2 months versus 6.9 months for the control group, indicating strong clinical applicability.
- Significant Efficacy: The combination achieved an objective response rate of 60.5%, significantly higher than the control group's 24.3%, with a median duration of response of 23.7 months, showcasing consistent efficacy across various IMDC prognostic risk groups and reinforcing its therapeutic position.
- Market Impact: This approval marks the tenth indication for TYVYT in China, highlighting its role as a widely used PD-1 inhibitor in the oncology landscape and providing new treatment options for patients, addressing the urgent need for second-line therapies.
See More
